Here is the note from our CEO, Goran Dubravcic:
“PHI and Altium share the same vision that regenerative medicine will transform healthcare and cure presently incurable diseases. In this transformation of medicine, we see PHI’s noninvasive cell analysis method as a keystone of standardizing quality control in clinical biomanufacturing. In addition, the expertise of PHI and the proven technology is an outstanding fit with our organizational development vision.
Altium is constantly striving to grow and expand. So naturally, we want to be part of this technology leap, and by investing in PHI, we ensure to provide excellence for the society we live in.”